Gallic acid-based indanone derivative interacts synergistically with tetracycline by inhibiting efflux pump in multidrug resistant E. coli

Applied Microbiology and Biotechnology

Volumn 100, Issue 5, 2016, Pages 2311-2325

  Dwivedi, Gaurav Raj ^a,b   Tiwari, Nimisha ^a   Singh, Aastha ^a   Kumar, Akhil ^a   Roy, Sudeep ^a,c   Negi, Arvind Singh ^a   Pal, Anirban ^a   Chanda, Debabrata ^a   Sharma, Ashok ^a   Darokar, Mahendra P ^a  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

^b BABASAHEB BHIMRAO AMBEDKAR UNIVERSITY   (India)

^c BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

Author keywords

ATPase; Efflux pump inhibition; Gallic acid; Indanone derivative; Subacute oral toxicity; Synergy

Indexed keywords

ANTIBIOTICS; DRUG THERAPY; MAMMALS; TOXICITY;

ANTIBIOTIC EFFECTS; ATPASE; CLINICAL ISOLATES; EFFLUX PUMPS; ETHIDIUM BROMIDE; GALLIC ACIDS; MULTIDRUG RESISTANTS; SYNERGY;

ESCHERICHIA COLI;

(2 HYDROXYNAPHTHALEN 1 YL) (3,4,5 TRIMETHOXYPHENYL)METHANONE; 1,3 BIS(3,4,5 TRIMETHOXYPHENYL)PROP 2 EN 1 ONE; 3 (3' 4' 5' TRIMETHOXYPHENYL) 4,5,6 TRIMETHOXYINDANONE 1; ADENOSINE TRIPHOSPHATASE; ETHIDIUM BROMIDE; GALLIC ACID DERIVATIVE; INDANONE DERIVATIVE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; [3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA ACETATE 2YL] (3,4,5 TRIMETHOXYPHENYL) METHANONE; ANTIINFECTIVE AGENT; ENZYME INHIBITOR; GALLIC ACID; INDACRINONE; INDAN DERIVATIVE;

ANTIBIOTICS; BACTERIUM; BIOLOGICAL PUMP; DRUG RESISTANCE; ENZYME ACTIVITY; ORGANIC ACID; ORGANIC COMPOUND; PHENOLIC COMPOUND; RODENT; TOXICITY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; ATPASE ACTIVITY ASSAY; BACTERIAL GENE; BACTERIUM ISOLATE; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TRANSPORT; EFFLUX PUMP INHIBITION; ENZYME IMMUNOASSAY; ENZYME INHIBITION; ESCHERICHIA COLI; FEMALE; MACB GENE; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; OMPA GENE; OMPX GENE; PERITONEUM MACROPHAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPTICEMIA; UPREGULATION; YOJI GENE; ADVERSE DRUG REACTION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; MACROPHAGE; MICROBIAL SENSITIVITY TEST; ORAL DRUG ADMINISTRATION; SHOCK, SEPTIC;

ESCHERICHIA COLI; MUS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME INHIBITORS; ESCHERICHIA COLI; GALLIC ACID; INDANS; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; SHOCK, SEPTIC; TETRACYCLINE;

EID: 84958900207     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-015-7152-6     Document Type: Article

References (67)

1. Bambeke FV, Glupczynski Y, Plesiat P, Pechère JC, Tulkens PM (2003) Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 51:1055–65
2. Centers for Disease Control and Prevention (CDC) (2013) Multidrug-resistant organism & clostridium difficile infection (MDRO/CDI) module. CDC 12:2–42
3. Chanda D, Shanker K, Pal A, Luqman S, Bawankule DU, Mani D, Darokar MP (2009) Safety evaluation of trikatu, a generic ayurvedic medicine in Charles Foster rat. J Toxicol Sci 34:99–108
4. Clinical and Laboratory Standards Institute (CLSI) (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—ninth edition: approved standard M07-A9. CLSI, Wayne
5. Craig WA, Gudmundsson S (1991) The postantibiotic effect. In: Lorian V (ed) Antibiotics in laboratory medicine, 3rd edn. Williams & Wilkins, Baltimore, pp 403–31
6. Datta S, Wattal C, Goel N, Oberoi JK, Raveendran R, Prasad KJ (2012) A ten year analysis of multidrug resistant blood stream infections caused by Escherichia coli & Klebsiella pneumoniae in tertiary care hospital. Indian J Med Res 135:907–12
7. Dixon RE (2011) Control of health care associated infections 1961–2011. CDC MMWR 60:S58–S63
8. Dwivedi GR, Gupta S, Roy S, Kalani K, Pal A, Thakur JP, Saikia D, Sharma A, Darmwal NS, Darokar MP, Srivastava SK (2013) Tricyclic sesquiterpenes from Vetiveria zizanoides (L.) Nash as antimycobacterial agents. Chem Biol Drug Des 82:587–594
9. Dwivedi GR, Yadav DK, Singh V, Srivastava SK, Khan F, Darmwal NS, Darokar MP (2014) 4-Hydroxy-α-tetralone and its derivative as drug resistance reversal agents in multi drug resistant Escherichia coli. Chem Biol Drug Des 83:482–492
10. Dwivedi GR, Maurya A, Yadav DK, Khan F, Darokar MP, Srivastava SK (2015) Drug resistance reversal potential of ursolic acid derivatives against nalidixic acid and multidrug resistant Escherichia coli. Chem Biol Drug Des 86:272–283
11. Eliopoulos GM, Wennersten CB (2002) Antimicrobial activity of quinupristin–dalfopristin combined with other antibiotics against vancomycin resistant enterococci. Antimicrob Agents Chemother 46:1319–24
12. Eliopoulus GM, Moellering RCJ (1996) Antimicrobial combinations. In: Lorian V (ed) Antibiotics in laboratory medicine, 4th edn. Williams & Wilkins, Baltimore, pp 330–6
13. Eswaran J, Koronakis E, Higgins MK, Hughes C, Koronakis V (2004) Three’s company: component structures bring a closer view of tripartite drug efflux pumps. Curr Opin Struct Biol 14:741–47
14. Gallay P, Heumann D, Le Roy D, Barras C, Glauser MP (1994) Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc Natl Acad Sci U S A 91:7922–6
15. Gaynes R, Edwards JR (2005) Overview of nosocomial infections caused by gram negative bacilli. Clin Infect Dis 41:848–854
16. Gertsch J (2011) Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Planta Med 77:1086–98
17. Glavinas H, Méhn D, Jani M, Oosterhuis B, Heredi-Szabo K, Krajcsi P (2008) Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. Expert Opin Drug Metab Toxicol 4:721–32
18. Gould IM (2009) Antibiotic resistance: the perfect storm. Int J Antimicrob Agents 4:S2–S5
19. Gupta VK, Verma S, Pal A, Srivastava SK, Srivastava PK, Darokar MP (2013) In vivo efficacy and synergistic interaction of 16α-hydroxycleroda-3, 13 (14) Z-dien-15, 16-olide, a clerodane diterpene from Polyalthia longifolia against methicillin-resistant Staphylococcus aureus. Appl Microbiol Biotechnol 97:9121–9131
20. Hassani M (2014) The crisis of resistant gram-negative bacterial infections: is there any hope for ESKAPE? Clin Infect Dis 1:1005
21. Hawkey PM, Jones AM (2009) The changing epidemiology of resistance. J Antimicrob Chemother 64:S1–S10
22. Heisig P, Tschorny R (1994) Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 38:1284–91
23. Hurdle JG, O’Neill AJ, Chopra I, Lee RE (2011) Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 9:62–75
24. Infectious Diseases Society of America (2010) The 10 × 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50:1081–1083
25. Ivanova A, Batovska D, Engi H, Ocsovszki I, Kostova I, Molnar J (2008) MDR-reversal activity of chalcones. In Vivo 22:379–384
26. Jia J, ZhuF MF, Cao Z, Li Y, Chen YZ (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8:111–28
27. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P (2008) Global trends in emerging infectious diseases. Nature 451:990–993
28. Kaatz GW, Moudgal VV, Seo SM, Kristiansen JE (2003) Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother 47:719–26
29. Khan AA, Slifer TR, Araujo FG, Suzuki Y, Remington JS (2000) Protection against lipopolysaccharide-induced death by fluoroquinolones. Antimicrob Agents Chemother 44:3169–73
30. Khan IA, Mirza ZM, Kumar A, Verma V, Qazi GN (2006) Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 50:810–812
31. Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller A, Schaberle TF, Hughes DE, Epstein S, Jones M, Lazarides L, Steadman VA, Cohen DR, Felix CR, Fetterman KA, Millett WP, Nitti AG, Zullo AM, Chen C, Lewis K (2015) A new antibiotic kills pathogens without detectable resistance. Nature 517:455–9
32. Livermore DM (2009) Has the era of untreatable infections arrived? J Antimicrob Chemother 64(S):i29–i36
33. Lomovskaya O, Watkins WJ (2001) Efflux pumps: their role in antibacterial drug discovery. Curr Med Chem 8:1699–1711
34. Lubelski J, Konings WN, Driessen AJM (2007) Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev 71:463–476
35. Marquez B (2005) Bacterial efflux systems and efflux pumps inhibitors. Biochimie 87:1137–1147
36. Martins M, Sujata GD, Fanning S, Kristiansen JE, Molnar J, Pagès JM, Schelz Z, Spengler G, Viveiros M, Amaral L (2008) Potential role of non-antibiotics in the treatment of multidrug-resistant gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents 31:198–208
37. Maurya A, Dwivedi GR, Darokar MP, Shrivastava SK (2013) Antibacterial and synergy of clavine alkaloid lysergol and its derivatives against nalidixic acid resistant Escherichia coli. Chem Biol Drug Des 81:484–90
38. McMurry LM, Petrucci RE, Levy SB (1980) Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc Natl Acad Sci U S A 77:3974–7
39. Negi AS, Darokar MP, Chattopadhyay SK, Garg A, Bhattacharya AK, Srivastava V, Khanuja SP (2005) Synthesis of a novel plant growth promoter from gallic acid. Bioorg Med Chem Lett 15:1243–1247
40. Nikaido H (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 67:593–656
41. Nikaido H (2009) Multidrug resistance in bacteria. Annu Rev Biochem 78:119–46
42. Nordmann P, Dortet L, Poirel L (2012) Carbapenem resistance in enterobacteriaceae: here is the storm! Trends Mol Med 18:263–72
43. O’Neill LA (2006) Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 5:549–563
44. Odds FC (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1
45. Pages JM, Amaral L (2009) Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of gram-negative bacteria. Biochim Biophys Acta 1794:826–833
46. Parihar S, Gupta A, Chaturvedi AK, Agarwal J, Luqman S, Changkija B, Manohar M, Chanda D, Chanotiya CS, Shanker K, Dwivedi A, Konwar R, Negi AS (2012) Gallic acid based steroidal phenstatin analogues for selective targeting of breast cancer cells through inhibiting tubulin polymerisation. Steroids 77:878–886
47. Peleg AY, Hooper DC (2010) Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362:1804–13
48. Poole K (2001) Multidrug resistance in gram-negative bacteria. Curr Opin Microbiol 4:500–8
49. Poole K (2007) Efflux pumps as antimicrobial resistance mechanisms. Ann Med 39:162–176
50. Reddy GD, Kumar KNVP, Duganath N, Raavi D, Amitha K (2012) ADMET, docking studies & binding energy calculations of some novel ACE-inhibitors for the treatment of diabetic nephropathy. Int J Drug Dev Res 4:268–282
51. Richards CD, Gauldie J (1995) Role of cytokines in acute phase response. In: Agarwal BB, Puri RK (eds) Human cytokines: their role in disease and therapy. Blackwell Science, Cambridge, pp 253–69
52. Roberts MC (2003) Tetracycline therapy: update. Clin Infect Dis 36:462–7
53. Roberts L, Simpson S (2008) Deadly defiance. Science 321:355–361
54. Saxena HO, Faridi U, Srivastava S, Kumar JK, Darokar MP, Luqman S, Chanotiya CS, Krishna V, Negi AS, Khanuja SP (2008) Gallic acid based indanone derivatives as anticancer agents. Bioorg Med Chem Lett 18:3914–3918
55. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4. J Exp Med 189:1777–1782
56. Speer BS, Shoemaker NB, Salyers AA (1992) Bacterial resistance to tetracycline: mechanisms, transfer and clinical significance. Clin Microbiol Rev 5:387–399
57. Spellberg B, Bartlett JG, Gilbert DN (2013) The future of antibiotics and resistance. N Engl J Med 368:299–302
58. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K (2000) Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5*-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci U S A 97:1433–1437
59. +- ATPase of the facultative anaerobic alkaliphile, Exiguobacterium auranticum. Biochim Biophys Acta 1727:162–168
60. Tikhonova EB, Zgurskaya HI (2004) AcrA, AcrB, andTolC of Escherichia coli form a stable inter membrane multidrug efflux complex. J Biol Chem 279:32116–24
61. Upadhyay HC, Dwivedi GR, Darokar MP, Chaturvedi V, Srivastava SK (2012) Bioenhancing and antimycobacterial agents from Ammania, multiflora. Planta Med 78:79–81
62. Upadhyay HC, Dwivedi GR, Roy S, Sharma A, Darokar MP, Srivastava SK (2014) Phytol derivatives as drug resistance reversal agents. ChemMedChem 9:1860–1868
63. Vaara M (1993) Antibiotic-super susceptible Mutants of Escherichia coli and Salmonella typhimurium. Antimicrob Agents Chemother 37:2255–2260
64. van der Donk CF, van de Bovenkamp JH, De Brauwer EI, De Mol P, Feldhoff KH, Kalka-Moll WM, Nys S, Thoelen I, Trienekens TA, Stobberingh EE (2012) Antimicrobial resistance and spread of multi drug resistant Escherichia coli isolates collected from nine urology services in the Euregion Meuse-Rhine. PLoS One 7:e47707
65. Viveiros M, Jesus A, Brito M, Leandro C, Martins M, Ordway D, Molnar AM, Molnar J, Amaral L (2005) Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes. Antimicrob Agents Chemother 49:3578–82
66. Viveiros M, Dupont M, Rodrigues L, Couto I, Davin-Regli A, Martins M, Pagès JM, Amaral L (2007) Antibiotic stress, genetic response and altered permeability of E. coli. PLoS ONE 2:e365
67. Viveiros M, Rodrigues L, Martins M, Couto I, Spengler G, Martins A, Amaral L (2010) Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. Methods Mol Biol 642:159–72